Log In
BCIQ
Print this Print this
 

RTL1000

  Manage Alerts
Collapse Summary General Information
Company Artielle ImmunoTherapeutics Inc.
DescriptionRecombinant T cell receptor (TCR) ligand
Molecular Target Myelin oligodendrocyte glycoprotein (MOG)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation U.S. - Orphan Drug (Treat multiple sclerosis (MS))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today